LEADER 04148nam 2201033z- 450 001 9910576881503321 005 20231214133145.0 035 $a(CKB)5720000000008360 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84478 035 $a(EXLCZ)995720000000008360 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMitochondria-targeted drug delivery 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (290 p.) 311 $a3-0365-4039-3 311 $a3-0365-4040-7 330 $aMitochondria, organelles surrounded by a double membrane and with their own small genome, are the cells? energy centers. Besides the production of ATP through cellular respiration, mitochondria play a pivotal role in other aspects of the life and death of a cell: heat production, programmed cell death, the regulation of metabolic activity, immunity, and calcium homeostasis. A number of diseases are associated with mitochondrial dysfunction, including cardiovascular, neurological, inflammatory, and metabolic disorders as well as cancer. Mitochondria therefore represent an important therapy target, and it is not surprising that a number of different treatment strategies have emerged. Approaches targeting mitochondria can be split into two opposite categories: drugs that restore mitochondrial function and drugs that trigger mitochondria-mediated cell death. Targeted drug delivery to achieve the selective accumulation of drug molecules in mitochondria is complex and involves methods such as direct drug modification or encapsulation into nanocarriers. 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 610 $aretinal ischemia 610 $ablood-brain barrier 610 $aendothelial 610 $areactive oxygen species 610 $aoxidative stress 610 $atunneling nanotubules 610 $aneuron 610 $acentral nervous system 610 $ainflammation 610 $ahypoxia 610 $aanticancer peptide (ACP) 610 $aantimicrobial peptide (AMP) 610 $aanticancer peptides 610 $aantimicrobial peptides 610 $ahost defense peptides 610 $aprediction 610 $arandom forest 610 $amitochondria 610 $amitochondrial DNA 610 $amitochondrial disorders 610 $apharmacological therapy 610 $agene therapy 610 $aprecision medicine 610 $acardiovascular disease 610 $adrug delivery 610 $amitochondria dysfunctions 610 $ananocarriers 610 $aoxoglutarate carrier 610 $amalate-aspartate shuttle 610 $acancer metabolism 610 $aATP production 610 $adiphenyleneiodonium 610 $aNADPH-oxidase 610 $adifferentiation 610 $aproliferation 610 $amitochondria-targeted antioxidants 610 $aLPS 610 $amitochondrial ROS 610 $aantitumor agents 610 $afluorescence lifetime imaging 610 $amedicinal chemistry 610 $ametabolic drug 610 $amitochondrial carrier 610 $amelanoma 610 $aplumbagin 610 $acytotoxic effect 610 $ametabolism 610 $acholesterol 610 $alipid raft 610 $amitochondrial permeability transition pore 610 $aalkylphospholipid analog 610 $aedelfosine 610 $amitochondrial oncometabolites 610 $acancer drug resistance 610 $amitochondrial disease 610 $aheteroplasmy 610 $amitochondrial gene delivery 615 7$aResearch & information: general 615 7$aBiology, life sciences 700 $aKopecka$b Joanna$4edt$01326492 702 $aKopecka$b Joanna$4oth 906 $aBOOK 912 $a9910576881503321 996 $aMitochondria-targeted drug delivery$93037563 997 $aUNINA